Resistance in the Ribosome: RUNX1, pre-LSCs, and HSPCs.
作者:
Ito(Kyoko),Ito(Keisuke)
状态:
发布时间2015-08-08
, 更新时间 2016-10-25
期刊:
Cell Stem Cell
摘要:
Therapeutic targeting of pre-leukemic stem cells (pre-LSCs) may be a viable strategy to eradicate residual disease and prevent leukemia relapse. Now in Cell Stem Cell, Cai et al. (2015) show that loss-of-function mutations in RUNX1 reduce ribosome biogenesis and provide pre-LSCs a selective advantage over normal hematopoietic cells through increased stress resistance.